Evestia Clinical Acquires Emtex Life Science

Evestia Clinical has acquired Emtex Life Science, according to GlobeNewswire. The announcement describes the transaction as a step to further enhance Evestia Clinical’s global full-service clinical research capabilities.

GlobeNewswire reports that the acquisition significantly expands the depth and scale of Evestia Clinical’s established medical writing capabilities for biotech innovators. The transaction brings Emtex Life Science into Evestia Clinical’s clinical research offering, with medical writing identified as the central area of expansion in the announcement.

Medical writing is the stated focus

The announcement centers on Evestia Clinical’s established medical writing capabilities. GlobeNewswire says the acquisition significantly expands both the depth and scale of those capabilities for biotech innovators.

Evestia Clinical characterized the acquisition within its global full-service clinical research capabilities. GlobeNewswire’s report links the Emtex Life Science acquisition directly to that broader clinical research focus while specifically highlighting medical writing.

What GlobeNewswire reports

• Evestia Clinical acquired Emtex Life Science.
• The acquisition significantly expands the depth and scale of Evestia Clinical’s established medical writing capabilities.
• Biotech innovators are identified in connection with the expanded medical writing capabilities.
• The transaction is presented as further enhancing Evestia Clinical’s global full-service clinical research capabilities.

Relevance for pharma and biotech sales professionals

For pharmaceutical and biotech sales professionals, the announcement highlights an acquisition involving clinical research services and medical writing. GlobeNewswire frames the transaction around the expansion of Evestia Clinical’s existing capabilities rather than a change to a single service area alone.

The report identifies two connected themes: expanded medical writing capabilities for biotech innovators and Evestia Clinical’s global full-service clinical research capabilities. Sales professionals tracking clinical research service providers can note the stated emphasis on increased depth and scale following the acquisition.

GlobeNewswire’s announcement does not provide further transaction details in the supplied report. Its stated focus remains Evestia Clinical’s acquisition of Emtex Life Science and the resulting expansion of medical writing capabilities within Evestia Clinical’s clinical research offering.